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ABSTRACT
Background and aims: Effective glycemic control is the cornerstone of successful type 2 diabetes
management. However, many patients fail to reach glycemic control targets, and therapeutic inertia
(failure to intensify therapy to address poor glycemic control in a timely manner) has been widely
reported. The aim of the present study was to evaluate the economic burden associated with dia-
betes-related complications due to poor glycemic control for patients with type 2 diabetes in the UK.
Methods: A validated long-term model of type 2 diabetes (IQVIA CORE Diabetes Model) was used to
project cost outcomes for a UK population with type 2 diabetes, based on data from The Health
Improvement Network primary care database, at different levels of glycemic control. Costs associated
with diabetes-related complications were accounted in 2017 Pounds Sterling (GBP). Complication costs
were estimated for populations achieving different glycated hemoglobin (HbA1c) targets, in a number
of delayed treatment intensification scenarios, and across a range of time horizons.
Results: For patients with an HbA1c level of 8.2% (66mmol/mol), 7 years in poor control could
increase mean costs associated with diabetes-related complications by over GBP 690 per patient and
lead to costs of over GBP 1,500 in lost workplace productivity compared with achieving good glycemic
control (HbA1c 7.0%, 53mmol/mol) over a 10-year time horizon. Based on published estimates of the
proportion of type 2 diabetes patients failing to meet glycemic targets in the UK, this corresponds to
an additional economic burden of GBP 2,600 million (complication costs plus lost productivity costs).
Conclusions: The economic burden of poor glycemic control in type 2 diabetes in the UK is substan-
tial. Efforts to avoid therapeutic inertia could substantially reduce diabetes-related complication costs
even in the short-term.
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Introduction
With 422 million people around the world living with the
disease and incidence rates continuing to rise, diabetes melli-
tus represents one of the most serious challenges facing
healthcare systems around the world1. Type 2 diabetes in
particular, which contributes 90% of all cases of diabetes
mellitus, is the main driver of increasing prevalence with esti-
mates suggesting that the number of people living with dia-
betes has doubled since 19801,2. Diabetes mellitus is a
chronic, metabolic disease associated with significant mor-
bidity and mortality, and characterized by elevated levels of
blood glucose, which eventually leads to serious damage to
the heart, blood vessels, eyes, kidneys, and nerves1. Diabetes
UK has estimated that 4.7 million people in the UK have
been diagnosed with diabetes mellitus, leading to the
National Health Service (NHS) spending GBP 10 billion per
year on the disease; around 10% of its overall budget2,3.
Moreover, evidence has indicated that 80% of the total
cost of diabetes mellitus is associated with the management
of complications3. However, several landmark studies have
shown that maintaining good glycemic control can reduce
the incidence of diabetes-related complications in the long-
term, creating the potential to improve patient outcomes
and reduce the burden of disease4–8. Based on these data,
the National Institute for Health and Clinical Excellence
(NICE) recommends glycemic control targets for patients
with type 2 diabetes9. For those managed with lifestyle mod-
ifications and a single drug not associated with hypogly-
cemia, a glycated hemoglobin (HbA1c) target of 6.5%
(48mmol/mol) or below is recommended, and for those with
diabetes not adequately controlled with monotherapy, a tar-
get of 7.0% (53mmol/mol) or below is suggested. The guide-
lines further recommend that therapy should be intensified if
HbA1c is greater than 7.5% (58mmol/mol).
In 2017, Khunti and Millar-Jones10 published a literature
review focused on therapeutic inertia in type 2 diabetes, or
failure to intensify therapy despite poor glycemic control, in
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the UK. The authors reported evidence that clinicians tend to
have a reactive approach to therapy intensification, waiting
for the worsening of hyperglycemia or complications to arise
before intensifying treatment, and as a result patients will
reach glycemic targets for only short periods, if at all.
Median times to intensification with insulin therapy were
6–7 years for patients on multiple oral antidiabetic drugs
(OADs) and one study reported a median of 3.7 years [95%
confidence interval ¼ 3.4–4.0] for the intensification of insu-
lin therapy from the time that high HbA1c levels (7.5%
[58mmol/mol]) were recorded11–13.
Recent evidence indicates that many patients with dia-
betes mellitus in the UK are not achieving the glycemic tar-
gets recommended by NICE14,15. Data from the National
Diabetes Audit has shown that one-third of people with type
2 diabetes in England and Wales had an HbA1c above 7.5%
(58mmol/mol) in 2016–201714. Similarly, estimates from
Scotland have suggested that around 40% of people with
type 2 diabetes have an HbA1c above 7.5% (58mmol/mol)16.
These figures suggest that there is an opportunity to bring a
greater proportion of people with type 2 diabetes into good
glycemic control and, in combination with addressing other
modifiable risk factors through optimized therapy, reduce
the costs associated with diabetes-related complications for
healthcare payers and UK society as a whole.
The aim of the present study was to evaluate the eco-
nomic burden associated with diabetes-related complications
due to poor glycemic control for patients with type 2 dia-
betes in the UK.
Methods
Modeling approach
Long-term projections of clinical and cost outcomes were
made using the IQVIA CORE Diabetes Model (version 9.0), a
non-product specific diabetes policy analysis tool that has
been validated against real-life data on original publication
in 2004 and more recently in 201417,18. The architecture,
assumptions, features, and capabilities of the model have
been previously published19. The model was used to evalu-
ate complication rates, costs associated with diabetes-related
complications, and costs arising from lost workplace product-
ivity, including losses due to premature mortality. UK-specific
life tables for 2015 from the World Health Organization were
used for all analyses to capture background mortality, with
remaining mortality due to diabetes-related complications
also captured20. The risk of cardiovascular complications was
predicted using the UKPDS 68 equations21. All simulations
were performed using a first-order Monte Carlo approach.
Outcomes were projected over 3, 5, 10, 15, and 20 years,
as well as patients’ lifetimes (Table 1). Scenarios evaluated
outcomes with baseline HbA1c at 8.2% (66mmol/mol), in
line with the baseline value in the THIN population initiating
therapy, and 9.0% (75mmol/mol), with target levels set to
6.5% (48mmol/mol, in line with NICE guidance), 7.0%
(53mmol/mol), and 7.5% (58mmol/mol) in separate analyses
(Table 1). In line with published evidence from the UK, add-
itional scenarios modeled intensifying patients immediately
(within year 1) compared with a delay in intensification of 1,
3, 5, or 7 years (in line with Khunti and Millar Jones10). In the
modeling analysis, simulated patients were assumed to main-
tain good glycemic control (at a target HbA1c level), or to be
in poor glycemic control (at the baseline HbA1c level) for a
defined time period before HbA1c was lowered to the target
level for the remainder of the time horizon (or the patient
died in the simulation).
Cohort characteristics
Baseline patient characteristics were derived primarily from
the population initiating therapy in the THIN primary care
database in the UK, used by NICE in the health economic
analysis supporting the development of guideline NG28
(published in December 2015)22. People with type 2 diabetes
were selected from the THIN dataset using a combination of
read codes for type 2 diabetes, and initial therapy baseline
data were selected from people receiving their first single
non-insulin anti-diabetes medication. Data were selected for
the point at which people were first prescribed anti-diabetes
medication other than insulin, with measurements recorded
closest to the prescription date (± 6months). Patients were
modeled with a baseline mean (standard deviation) age of
59.8 (12.6) years, mean duration of diabetes of 2.0 years, pro-
portion male of 57.1%, proportion smokers of 19.1%, mean
HbA1c of 8.2 (2.0)% (66mmol/mol), mean systolic blood
pressure of 139.6 (17.1) mmHg, mean total cholesterol of
4.96 (1.15) mmol/L, and mean body mass index (BMI) of 31.9
(3.2) kg/m2 (see Supplementary Material for details). Missing
values were supplemented with those from the trial popula-
tion described by Pratley et al.23, as these values were not
available from the THIN dataset and the trial population was
comparable in terms of baseline demographics to the popu-
lation initiating therapy in THIN, while mean number of ciga-
rettes per day and alcohol consumption were based on
UK-specific data for the general population24,25. Where data
could not be sourced from either THIN or Pratley et al.
cohorts, characteristics were set to IQVIA CORE Diabetes
Model default values. This cohort was assumed to be repre-
sentative of patients in the UK early in the type 2 diabetes
treatment continuum. Use of IQVIA CORE Diabetes Model
Table 1. Overview of scenarios modeled.
Baseline HbA1c
% (mmol/mol)
Target HbA1c
% (mmol/mol)
Time to target Time horizon
8.2 (66) 6.5 (48)
7.0 (53)
7.5 (58)
Year 1 vs
Delayed by 1 year
Delayed by 3 years
Delayed by 5 years
Delayed by 7 years
3 years
5 years
10 years
15 years
20 years
Lifetime
9.0 (75) 6.5 (48)
7.0 (53)
7.5 (58)
Year 1 vs
Delayed by 1 year
Delayed by 3 years
Delayed by 5 years
Delayed by 7 years
3 years
5 years
10 years
15 years
20 years
Lifetime
Results from these scenarios are presented in Tables 1 and 2 and in the
Supplementary Material. Results from all other scenarios can be provided on
request.
Abbreviation. HbA1c, glycated hemoglobin.
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default values in the modeling analysis was anticipated to
have a modest impact on projected outcomes as these were
derived from the UK Prospective Diabetes Study population,
which was a newly-diagnosed UK type 2 diabetes cohort ini-
tiating therapy (in line with THIN population described
above), and given that data for all key risk factors were taken
from the THIN population (see Supplementary Table S1 for
further details). Baseline HbA1c varied between 9.0%
(75mmol/mol) and 7.5% (58mmol/mol) in scenario analyses.
Costs and other model settings
Costs associated with diabetes-related complications were
derived from published sources and expressed in 2017
Pounds Sterling (GBP) (see Supplementary Material for
details). No costs of glucose-lowering therapy were included
in the analysis. Costs associated with lost workplace product-
ivity were evaluated based on days off work estimates pub-
lished by Sørensen and Ploug26 and country-specific
estimates of mean salaries in simulated patients of working
age (see Supplementary Material for details). Physiological
parameter progression was assumed to remain constant over
the duration of the analyses, to enable the comparison of
different HbA1c targets and baseline levels. Future cost out-
comes were discounted at 3.5% annually in line with pub-
lished guidance, and undiscounted results are provided in
the Supplementary Material.
Estimation of burden
A prevalence-based approach was used to estimate the
country-level burden associated with poor glycemic control.
Per patient differences in direct and indirect costs were mul-
tiplied by estimates of the number of patients in poor gly-
cemic control based on the literature: 2,887,213 of the
3,208,014 patients with diabetes in the UK have type 2 dia-
betes27; 1,163,547 patients are in poor glycemic control
(based on data from de Pablos-Velasco et al.15) stating that
40.3% of these patients are in poor control11. An incidence-
based calculation to estimate burden was also performed.
Published incidence data provides an estimate of the num-
ber of these patients in the healthcare system in each year,
and therefore allows calculation of the burden of therapeutic
inertia over a 40-year period. This can be thought of as the
burden associated with therapeutic inertia in the 2018
incident cohort, plus the 2019 incident cohort, plus the 2020
incident cohort, and so on (through to the end of 2057),
based on the incidence data published by Zghebi et al.28.
Full details of this approach are provided in the
Supplementary Material.
Results
Cost savings per patient
Long-term projections showed that 7 years in poor control
could have a substantial impact on costs and clinical out-
comes in patients with type 2 diabetes in the UK. For
patients with an HbA1c level of 8.2% (66mmol/mol), in line
with data from the THIN primary care database, 7 years in
poor control could increase mean direct costs by over GBP
690 and lead to mean costs of over GBP 1,500 in lost work-
place productivity over a 10-year time horizon compared
with achieving good glycemic control (HbA1c 7.0%,
53mmol/mol) (Table 2). Over patients’ lifetimes, the eco-
nomic burden was projected to be even higher, with 7 years
in poor control adding over GBP 1,250 on average to direct
medical costs and over GBP 1,600 in lost workplace product-
ivity for each patient not achieving good glycemic control
(HbA1c 7.0%, 53mmol/mol). Estimation of the patient-level
economic burden of just 1 year in poor glycemic control
(HbA1c 8.2% [66mmol/mol] vs 7.0% [53mmol/mol]) showed
that even with a short duration of poor glycemic control the
economic impact was substantial (Table 3). Total costs (mean
complication and lost productivity costs) were over GBP 835
higher with 1 year in poor glycemic control over patients’
lifetimes, and notable increases in costs were already evident
after only 3 years. A similar pattern of results was observed
when poor control was defined as a mean HbA1c of 9.0%
(75mmol/mol) in the modeling analysis, with an even greater
economic burden associated with poor glycemic control
(Tables 4 and 5).
Population level burden
Estimation of the economic burden at a population level,
based on published estimates of patients with type 2 dia-
betes failing to meet glycemic control targets, indicated that
7 years in poor glycemic control (HbA1c 8.2%, 66mmol/mol)
increased the direct costs associated with diabetes-related
Table 2. Cost savings associated with diabetes-related complications avoided for patients reaching glycemic targets (HbA1c 7.0% [53
mmol/mol]) vs having poor glycemic control HbA1c 8.2% [66 mmol/mol] for 7 years.
Time horizon
10 years 15 years Lifetime
Per patient outcomes
Savings due to complications avoided (GBP) 691.58 1,003.93 1,256.53
Savings due to lost productivity avoided (GBP) 1,542.77 1,558.35 1,606.35
Total cost savings (GBP) 2,234.34 2,562.28 2,862.88
Population outcomes
Savings due to complications avoided (GBP) 805 million 1,168 million 1,462 million
Savings due to lost productivity avoided (GBP) 1,795 million 1,813 million 1,869 million
Total cost savings (GBP) 2,600 million 2,981 million 3,331 million
Table shows discounted outcomes (3.5% per annum).
Abbreviations. GBP, British Pounds Sterling; HbA1c, glycated hemoglobin.
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complications by GBP 805 million over a 10-year time hori-
zon compared with good glycemic control (HbA1c 7.0%,
53mmol/mol) (Table 2). Costs associated with lost productiv-
ity in this scenario were projected to be GBP 1,795 million,
giving a total economic burden estimate of GBP 2,600 mil-
lion for 7 years of poor glycemic control at a population
level over a 10-year time horizon. Cardiovascular complica-
tions were the biggest driver of direct costs, accounting for
half of all direct medical costs in the modeled scenarios
(Figure 1). Over patients’ lifetimes, the total economic burden
of 7 years in poor glycemic control was estimated to be GBP
3,331 million in this scenario.
A substantial economic burden was evident even at much
shorter time horizons. Assuming poor glycemic control for
1 year (HbA1c 8.2%, 66mmol/mol), the modeling analysis
indicated the total additional costs (direct plus indirect costs)
were GBP 571 million after only 3 years vs maintaining
good glycemic control throughout (HbA1c 7.0%, 53mmol/
mol) (Table 3). This pattern of results was reflected when
modeling poor glycemic control at an HbA1c level of 9.0%
(75mmol/mol), with more pronounced savings (Tables 4
and 5, Figure 2).
Discussion
Delays in achieving good glycemic control in patients with
type 2 diabetes are likely to represent a huge economic bur-
den in the UK. The modeling analysis presented in this paper
was designed to evaluate the potential burden of time spent
in poor glycemic control, as reported in publications describ-
ing therapeutic inertia. The analysis showed that even a
short time (1 year) in poor glycemic control (HbA1c 8.2%,
66mmol/mol) could cost an additional GBP 197 million for
the management of diabetes-related complications over the
Table 4. Cost savings associated with diabetes-related complications avoided for patients reaching glycemic targets (HbA1c 7.0% [53
mmol/mol]) vs having poor glycemic control (HbA1c 9.0% [75 mmol/mol], for 7 years.
Time horizon
10 years 15 years Lifetime
Per patient outcomes
Savings due to complications avoided (GBP) 1,217.33 1,792.02 2,284.84
Savings due to lost productivity avoided (GBP) 2,679.48 2,612.27 2,752.01
Total cost savings (GBP) 3,896.81 4,404.29 5,036.85
Population outcomes
Savings due to complications avoided (GBP) 1,416 million 2,085 million 2,659 million
Savings due to lost productivity avoided (GBP) 3,118 million 3,039 million 3,202 million
Total cost savings (GBP) 4,534 million 5,125 million 5,861 million
Table shows discounted outcomes (3.5% per annum).
Abbreviations. GBP, British Pounds Sterling; HbA1c, glycated hemoglobin.
Table 5. Cost savings associated with diabetes-related complications avoided for patients reaching glycemic targets (HbA1c 7.0% [53
mmol/mol]) vs having poor glycemic control (HbA1c 9.0% [75 mmol/mol]) for 1 year.
Time horizon
3 years 5 years 10 years Lifetime
Per patient outcomes
Savings due to complications avoided (GBP) 126.51 188.78 306.06 453.78
Savings due to lost productivity avoided (GBP) 788.91 1,182.06 1,136.09 1,186.62
Total cost savings (GBP) 915.42 1,370.84 1,442.15 1,640.40
Population outcomes
Savings due to complications avoided (GBP) 147 million 220 million 356 million 528 million
Savings due to lost productivity avoided (GBP) 918 million 1,375 million 1,322 million 1,381 million
Total cost savings (GBP) 1,065 million 1,595 million 1,678 million 1,909 million
Table shows discounted outcomes (3.5% per annum).
Abbreviations. GBP, British Pounds Sterling; HbA1c, glycated hemoglobin.
Table 3. Cost savings associated with diabetes-related complications avoided for patients reaching glycemic targets (HbA1c 7.0% [53
mmol/mol]) vs having poor glycemic control HbA1c 8.2% [66 mmol/mol] for 1 year.
Time horizon
3 years 5 years 10 years Lifetime
Per patient outcomes
Savings due to complications avoided (GBP) 72.99 110.71 169.72 212.45
Savings due to lost productivity avoided (GBP) 417.57 712.95 668.49 622.97
Total cost savings (GBP) 490.56 823.65 838.21 835.42
Population outcomes
Savings due to complications avoided (GBP) 85 million 129 million 197 million 247 million
Savings due to lost productivity avoided (GBP) 486 million 830 million 778 million 725 million
Total cost savings (GBP) 571 million 958 million 975 million 972 million
Table shows discounted outcomes (3.5% per annum).
Abbreviations. GBP, British Pounds Sterling; HbA1c, glycated hemoglobin.
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Figure 1. Mean cost of diabetes-related complications associated with 7 years in poor control (HbA1c 9.0% or 8.2%) vs effective glycemic control (HbA1c 7.0%)
over a 10-year time horizon. Cardiovascular complications include myocardial infarction, angina, stroke, heart failure, and peripheral vascular disease. Renal compli-
cations include microalbuminuria, gross proteinuria, end-stage renal disease (dialysis), and renal transplant. Diabetic foot/neuropathy complications include foot
ulcers, peripheral neuropathy, and amputation. Ocular complications refer to all eye disease (retinopathy, macular edema, cataract, and severe vision loss).
Figure 2. Mean cost of diabetes-related complications associated with 1 year in poor control (HbA1c 9.0% or 8.2%) vs effective glycemic control (HbA1c 7.0%) over
a 10-year time horizon. Cardiovascular complications include myocardial infarction, angina, stroke, heart failure, and peripheral vascular disease. Renal complica-
tions include microalbuminuria, gross proteinuria, end-stage renal disease (dialysis), and renal transplant. Diabetic foot/neuropathy complications include foot
ulcers, peripheral neuropathy, and amputation. Ocular complications refer to all eye disease (retinopathy, macular edema, cataract, and severe vision loss).
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next 10 years. Factoring in lost workplace productivity, the
total cost of 1 year in poor glycemic control could be as
high as GBP 975 million over the next 10 years.
Whilst the present study is hypothetical in nature, much
of the data modeled was aligned with evidence from the
type 2 diabetes population in the UK. For example, cohort
characteristics were taken primarily from THIN primary care
database analysis used by NICE for the health economic ana-
lysis supporting the development of guideline NG28 and
HbA1c targets were aligned with those recommended by
NICE9,22. It is noteworthy that the NICE HbA1c targets are dif-
ferent dependent on patient characteristics and therapies,
and an individualized approach is recommended; therefore,
we included multiple HbA1c targets in the present analysis.
Assumptions around time in poor control were aligned with
the data published by Khunti and Millar-Jones10 in 2017,
indicating median times to intensification of 2.9 years from
OAD monotherapy to OAD dual therapy (see Supplementary
Material for 3-year delay results), 7.2 years from OAD dual to
triple therapy, and 6.7 years from OAD triple therapy to insu-
lin initiation. Complication costs were taken from published
UK-specific sources (see Supplementary Material) and lost
productivity costs were based on UK estimates of average
salaries, working days, and retirement age, albeit with days-
off-work estimates from a Danish study (as no UK-specific
estimates were identified in literature review). The accumula-
tion of lost workplace productivity costs in the modeling
simulations was observed to be primarily in the first few
years of the simulations, when the majority of patients were
below retirement age and therefore incurring lost workplace
productivity when complications occurred. With data sug-
gesting the diagnosis of type 2 diabetes is becoming increas-
ingly common in younger people, for example the National
Diabetes Audit 2016–2017 report 6,836 aged under 25 years
with the disease, the potential burden of lost workplace
productivity associated with the condition is vast10,29.
The estimates presented here are consistent with previous
analyses in the UK setting. For example, Baxter et al.30
reported that modest improvements in glycemic control
could generate significant reductions in the incidence and,
therefore, in the cost of complications in people with type 1
or type 2 diabetes based on a modeling analysis30. By projec-
ting outcomes for populations stratified by HbA1c, cost
reductions in the UK adult type 2 diabetes population associ-
ated with treating patients to NICE HbA1c targets were esti-
mated at GBP 299 million over 5 years, rising to GBP 4,506
million over 25 years. Hex et al.3 had previously reported
annual direct costs of diabetes-related complications of GBP
7,000 million in the type 2 diabetes population in 2010/2011,
and projected it could rise to GBP 12,224 million in 2035/
2036. Both of these studies provide evidence that improving
glycemic control in the type 2 diabetes population could
drive substantial reductions in the economic burden associ-
ated with the disease.
As with any modeling analysis, it is important to acknow-
ledge the limitations of the present study to appropriately
contextualize the findings. Modeling analyses that make
long-term projections of outcomes are, by definition,
associated with a degree of uncertainty. In the present ana-
lysis, a widely used, published, and validated health eco-
nomic model of type 2 diabetes (IQVIA CORE Diabetes
Model) was used to minimize this uncertainty17–19. The ana-
lysis used assumptions on HbA1c progression (constant lin-
ear progression) to facilitate the comparison between
different levels of glycemic control. Whilst this is almost cer-
tainly a simplification of reality (where HbA1c may vary con-
siderably across the population), it was an important part of
the analysis to allow clear interpretation of findings. Whilst
the focus of the present analysis was on quantifying the bur-
den associated with poor glycemic control, it is noteworthy
that effective management of patients with type 2 diabetes
involves addressing multiple risk factors, including reduction
of excess body weight, smoking cessation, and improving
blood pressure and serum lipid levels, amongst others31.
Therapeutic choices with the goal of achieving good gly-
cemic control can also impact these additional risk factors,
along with lifestyle factors and other medications. Targeting
multiple risk factors, not just glycemic control, in the man-
agement of patients with type 2 diabetes has the potential
to further reduce the economic burden associated with dia-
betes-related complications than the estimates reported in
the present analysis. Another potential limitation of the ana-
lysis was in the estimation of lost workplace productivity.
Limited data availability meant that separate estimates of
mean salary could not be used for males and females or
stratified by patient age. Given that the risk of several end
stage complications is generally higher in males, this may
lead to an under-estimation of the economic burden of dia-
betes-related complications. In addition, the impact of dia-
betes-related complications leading to enforced retirement
from the workforce or of their avoidance leading to delayed
retirement were not captured in the present analysis.
Hypoglycemia was not included in the study as the ana-
lysis was focused on evaluating the costs associated with
diabetes-related complications and not the costs of interven-
tions or their side-effects. That acknowledged, inclusion of
hypoglycemia in the present study would have had little or
no impact on the estimates of economic burden as the risk
of severe hypoglycemia would be unlikely to change signifi-
cantly over the HbA1c levels in the present analysis. Lipska
et al.32 reported comparable risk of severe hypoglycemia in
patients with HbA1c between 6.0 and 6.9% (42 and
52mmol/mol), 7.0 and 7.9% (53 and 63mmol/mol), 8.0 and
8.9% (64 and 74mmol/mol) in an analysis of over 9,000 type
2 diabetes patients in the US. Hypoglycemia risk was only
elevated in patients with low HbA1c levels (<6%, 42mmol/
mol) and high HbA1c levels (9%, 75mmol/mol). Moreover,
the risk of hypoglycemia can be mitigated by careful selec-
tion of medications that are associated with a lower risk of
hypoglycemia than traditional agents such as sulfonylurea
and human insulin33. Estimates of population level burden
were made using published prevalence data in line with pre-
vious studies30. It is worth noting, however, that this is likely
to under-estimate the true burden of disease and it only
quantifies clinical and cost outcomes for the prevalent
cohort. Incident patients, for example those who are
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diagnosed with type 2 diabetes next year or the year after
that, are not included in the prevalence-based estimates of
burden, but incidence-based estimates of burden are pro-
vided as additional information in the Supplementary
Material.
The present analysis did not include the costs of diabetes
therapy, as the aim was to evaluate the cost of complications
associated with poor glycemic control and providing an
accurate estimate of treatment costs was not possible within
the context of the analysis. It is noteworthy that additional
healthcare spending on glucose-lowering therapy would be
required for intensification and is, potentially, justified by the
findings of this study. Providing an accurate estimate of ther-
apy costs is challenging, given the wide array of therapeutic
options currently available to manage patients with type 2
diabetes and the individual variation in optimizing patients’
therapy to make the HbA1c improvements described in the
present analysis. Evaluating these costs, perhaps using a real-
life cohort stratified by HbA1c level to compare the use of
different therapies and associated costs, could represent an
interesting future avenue of research. Similarly, the routine
costs of management of diabetes patients were not included
in the present study. Whilst these costs would be expected
to be the same in patients in good glycemic control and
those in poor control, the survival paradox (whereby patients
who live longer cost more and are at risk of complications
for a longer period) may mean that patients in good gly-
cemic control accrue slightly higher routine management
costs than their counterparts in poor glycemic control,
although this would be expected to only have a very modest
impact on the outcomes of the analysis.
Conclusions
It is well established that the clinical and economic burden
of poor glycemic control in type 2 diabetes in the UK is sub-
stantial. The present modeling analysis indicates that efforts
to avoid delaying treatment intensification could reduce the
economic burden associated with diabetes-related complica-
tions. With published estimates suggesting that over 40% of
patients with type 2 diabetes in the UK have an HbA1c level
7% (53mmol/mol), there is a clear need to encourage ear-
lier intensification and address issues around therapeutic
inertia11,13. Model projections indicate that the benefits of
intensification would already be substantial at a population
level after only 3 years, and would continue to accumulate
over patients’ lifetimes.
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